<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534114</url>
  </required_header>
  <id_info>
    <org_study_id>21170</org_study_id>
    <secondary_id>2019-003927-39</secondary_id>
    <nct_id>NCT04534114</nct_id>
  </id_info>
  <brief_title>Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug</brief_title>
  <acronym>RE-THINc ESRD</acronym>
  <official_title>Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of BAY 2976217</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients whose kidneys are no longer able to work as they should and require treatment to&#xD;
      filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in&#xD;
      blood vessels (thrombosis) blocking blood flow that causes heart attacks, strokes, and other&#xD;
      life-threatening conditions. BAY2976217 is under clinical development for prevention of&#xD;
      thrombosis. The goal of the study is to learn more about the safety of BAY2976217, how it is&#xD;
      tolerated and the way the body absorbs, distributes and gets rid of the study dug given as&#xD;
      multiple doses in participants with renal impairment who require hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">May 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of major bleeding and clinically-relevant non-major bleeding during the main treatment period and within the on-treatment time window</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>As assessed by blinded Central Independent Adjudication Committee (CIAC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite of major bleeding and clinically-relevant non-major bleeding during the main and extended treatment periods and within the on-treatment time window</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>As assessed by blinded Central Independent Adjudication Committee (CIAC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs) during the main treatment period and within the on-treatment time window</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with TEAEs during the main and extended treatment periods and within the on-treatment time window</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with TEAEs during the main and extended treatment periods and until 20 weeks after the last study intervention dose</measure>
    <time_frame>Up to 64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with TEAEs categorized by severity during the main treatment period and within the on-treatment time window</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with TEAEs categorized by severity during the main and extended treatment periods and within the on-treatment time window</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with TEAEs categorized by severity during the main and extended treatment periods and until 20 weeks after the last study intervention dose</measure>
    <time_frame>Up to 64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentrations (Ctrough) of three dose levels of BAY2976217</measure>
    <time_frame>At visits V12 (Day 57), V14 (Day 85), V16 (Day 113), V18 (Day 141)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change in FXI antigen levels during the main treatment period</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change in FXI activity levels during the main treatment period</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">305</enrollment>
  <condition>End Stage Renal Disease Requiring Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Pooled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg BAY2976217</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg BAY2976217</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg BAY2976217</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY2976217</intervention_name>
    <description>Study intervention will be injected subcutaneously.</description>
    <arm_group_label>120 mg BAY2976217</arm_group_label>
    <arm_group_label>40 mg BAY2976217</arm_group_label>
    <arm_group_label>80 mg BAY2976217</arm_group_label>
    <other_name>Factor XI LICA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to BAY2976217 will be injected subcutaneously.</description>
    <arm_group_label>Pooled Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be at least 18 years of age at the time of signing the informed&#xD;
             consent form (ICF)&#xD;
&#xD;
          -  Participants with ESRD on hemodialysis (HD) for ≥3 months at the time of signing of&#xD;
             the ICF, receiving dialysis at least 9 hours a week and stable in the view of the&#xD;
             investigator&#xD;
&#xD;
          -  Male or female (contraceptive use by men or women should be consistent with local&#xD;
             regulations regarding the methods of contraception for those participating in clinical&#xD;
             studies)&#xD;
&#xD;
          -  Capable of giving signed ICF as described in the Protocol, which includes compliance&#xD;
             with the requirements and restrictions listed in the ICF and in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants receiving antiplatelet therapy except daily acetylsalicylic acid (ASA) ≤&#xD;
             150 mg/day&#xD;
&#xD;
          -  Participants receiving anticoagulation in therapeutic doses, other than standard&#xD;
             anticoagulation during the hemodialysis procedure&#xD;
&#xD;
          -  Known inherited bleeding disorder e.g. von-Willebrand disease or Hemophilia A, B or C&#xD;
&#xD;
          -  Recent (&lt;6 months before screening) clinically significant bleeding, or at high risk&#xD;
             of bleeding (in the judgement of the investigator)&#xD;
&#xD;
          -  Recent (&lt;3 months before screening) thromboembolic event, e.g. acute coronary&#xD;
             syndrome, stroke, or Venous thromboembolism (except dialysis access thrombosis)&#xD;
&#xD;
          -  Recent (&lt;3 months before screening) major surgery or scheduled major surgery during&#xD;
             participation in the study&#xD;
&#xD;
          -  Scheduled living donor renal transplant during study participation&#xD;
&#xD;
          -  Known Hepatitis B or C&#xD;
&#xD;
          -  Known HIV with recent documented detectable viral load (&lt;3 months before screening)&#xD;
&#xD;
          -  Persistent heart failure as classified by the New York Heart Association&#xD;
             classification of 3 or higher&#xD;
&#xD;
          -  Life expectancy less than 6 months&#xD;
&#xD;
          -  Sustained uncontrolled hypertension (persistent measurements of diastolic blood&#xD;
             pressure ≥ 100 mmHg, and/or systolic blood pressure ≥ 180 mmHg)&#xD;
&#xD;
          -  Hepatic disease associated with either: coagulopathy leading to a clinically relevant&#xD;
             bleeding risk, or ALT &gt; 3x ULN, or total bilirubin &gt;2x ULN with direct bilirubin &gt; 20%&#xD;
             of the total&#xD;
&#xD;
          -  Hb &lt; 9.0 g/dL at screening&#xD;
&#xD;
          -  Platelet count &lt; 120,000 mm3 at screening&#xD;
&#xD;
          -  Known hypersensitivity to the investigational drug or to inactive constituents of the&#xD;
             study intervention&#xD;
&#xD;
          -  Active malignancy requiring treatment during study participation (except non-melanoma&#xD;
             skin cancer, or cervical carcinoma in situ)&#xD;
&#xD;
          -  Participation in a study with an investigational medicinal product within 30 days or&#xD;
             within 5 half-lives of the previous administered drug, whichever is longer, prior to&#xD;
             the screening/observational period (Note: Participants from previous BAY 2306001/ISIS&#xD;
             416858 and BAY 2976217/ ION 957943 studies are eligible)&#xD;
&#xD;
          -  Any other conditions, which, in the opinion of the investigator or Sponsor would make&#xD;
             the subject unsuitable for inclusion&#xD;
&#xD;
          -  Confirmed pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fresenius Kidney Care Clovis</name>
      <address>
        <city>Clovis</city>
        <state>California</state>
        <zip>93611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Cities Dialysis-Amethyst &amp; Desert Cities Dialysis</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92392</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davita East Ft. Lauderdale Dialysis Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Kidney Care St. Louis Regional Dialysis</name>
      <address>
        <city>Saint Ann</city>
        <state>Missouri</state>
        <zip>63074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chromalloy Dialysis Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care - Fire Mesa Dialysis Unit</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Northwest Medical Center Dialysis</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Kidney Disease Center Physicians Group, PLLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salem VA Medical Center</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OL Vrouwziekenhuis - Campus Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionaal ZH Jan Yperman Campus Mariaziekenhuis</name>
      <address>
        <city>Ieper</city>
        <zip>8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Dialysis Services Bulgaria Ead</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Samokov</name>
      <address>
        <city>Samokov</city>
        <zip>2000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Knyaginya Klementina - Sofia&quot;EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT National Cardiology Hospital EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Etobicoke General Hospital</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9V 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare - Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health-Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de services ambulatoires de dialyse de Gaspé</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2T 3B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Québec-Université Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Frydek-Mistek</name>
      <address>
        <city>Frydek-Mistek</city>
        <zip>738 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klatovska nemocnice</name>
      <address>
        <city>Klatovy</city>
        <zip>339 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care - DS, s.r.o.</name>
      <address>
        <city>Melnik</city>
        <zip>276 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oblastni nemocnice Mlada Boleslav</name>
      <address>
        <city>Mlada Boleslav</city>
        <zip>293 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research Deutschland GmbH</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Resarch Germany GmbH</name>
      <address>
        <city>Geilenkirchen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52511</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein (UKSH)</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patra</name>
      <address>
        <city>Patra</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAPANIKOLAOU General Hospital Thessaloniki</name>
      <address>
        <city>Pilea Chortiatis</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz</name>
      <address>
        <city>Kalocsa</city>
        <zip>6300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsunami General Hospital</name>
      <address>
        <city>Hashima-gun</city>
        <state>Gifu</state>
        <zip>501-6062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Tokushukai Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>004-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibaraki Prefectural Central Hospital</name>
      <address>
        <city>Kasama</city>
        <state>Ibaraki</state>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Central Hospital of Matto Ishikawa</name>
      <address>
        <city>Hakusan</city>
        <state>Ishikawa</state>
        <zip>924-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Fujisawa Tokushukai Hospital</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <zip>251-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyu General Hospital</name>
      <address>
        <city>Hanyu</city>
        <state>Saitama</state>
        <zip>348-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical corporation association Shunshin-kai Inage hospital</name>
      <address>
        <city>Chiba</city>
        <zip>263-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Incheon St.Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Incheon Gwang''yeogsi</state>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeouido St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daugavpils Regional Hospital</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liepaja Regional Hospital</name>
      <address>
        <city>Liepaja</city>
        <zip>LV-3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P. Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidzemes Hospital</name>
      <address>
        <city>Valmiera</city>
        <zip>LV-4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Technology Center Clinic 1</name>
      <address>
        <city>Moscow</city>
        <zip>125466</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Nefroline-Novosibirsk&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Frezenius Nefrocare</name>
      <address>
        <city>Penza</city>
        <zip>440034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Dialysis center</name>
      <address>
        <city>Podolsk</city>
        <zip>142110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nikiforov All-Russian Center of Emergency and Radiation Med</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC B. Brown Avitum Russland Clinics</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193318</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Botkin clinical infectious diseases hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution City Hospital #26</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ciutat Sanitària i Universitària de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Principe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi- Mei Medical Hospital, Tai-Nan Hsien</name>
      <address>
        <city>Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Fresenius Medical Care Ukraine, LLC</name>
      <address>
        <city>Chernigiv</city>
        <zip>14034</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Center of Nephrology and Dialysis</name>
      <address>
        <city>Kyiv</city>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv Regional Clinical Hospital</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ternopil University Hospital</name>
      <address>
        <city>Ternopil</city>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporizhia Municipal Clinical Hospital No.10</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End stage renal disease (ESRD)</keyword>
  <keyword>Hemodialysis (HD)</keyword>
  <keyword>Thrombotic Events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

